Menu
Hawk Biosystems is excited to announce our participation in the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, which will take place from November 8-10, 2024, in Houston, Texas. As a leading event in the field of cancer immunotherapy, SITC 2024 offers a multidisciplinary forum aimed at improving cancer treatment outcomes through innovative strategies grounded in both basic and applied immunotherapy research.
This annual meeting will feature cutting-edge research presentations by experts, poster and oral abstract presentations, and numerous opportunities for both structured and informal discussions. The conference provides an important platform for networking and collaboration between academia, industry, regulatory agencies, and allied health professionals.
Hawk Biosystems will be presenting a poster on our latest findings, titled:“Beyond PD-L1: Unraveling the Enigma of Immunotherapy Response in PD-L1 Negative (<1%) NSCLC Patients through Quantification of PD-1/PD-L1 Engagement in the Tumour Microenvironment.”
Cristina Cacho, Scientific Officer, and Elena Castellano, Research Partnerships, will be attending the event and presenting the poster focused on exploring immunotherapy responses in non-small cell lung cancer (NSCLC) patients with PD-L1 negative (<1%) expression.
SITC 2024 is an excellent opportunity to connect with fellow scientists, clinicians, and industry leaders, and we are eager to engage in meaningful discussions that can further accelerate progress in cancer immunotherapy.
For more information about our work or to arrange a meeting during the event, please contact us
Stay connected
Subscribe to the HAWK Biosystems newsletter and don’t miss any news about our company, our products, events and much more.